LCTX SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 6, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 12, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 6, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 12, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 13, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Business Update

Aug 6, 2026

8-K

Lineage Cell Therapeutics Announces Annual Meeting Results and Withdrawal of CIRM Grant Application

Jun 12, 2026

8-K

Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Business Updates

May 12, 2026

8-K

Lineage Cell Therapeutics, Inc. Files Prospectus Supplement for At-the-Market Offering

Mar 11, 2026

8-K

Lineage Cell Therapeutics Reports Q4 and Full Year 2025 Results, Highlighting OpRegen Progress and Manufacturing Milestones

Mar 5, 2026

8-K

Lineage Cell Therapeutics withdraws CIRM OPC1 grant application; to resubmit in January 2026; DOSED trial unaffected

Nov 28, 2025

Prospectus

TYPE

HEADLINE

FILED AT

424B5

March 2026 ATM | Offering amount: $60,000,000 | Bank: B. Riley Securities

Mar 11, 2026

424B3

UPDATED | ATM | Offering amount: $39,966,424

Nov 12, 2025

424B5

Nov 21, 2024

424B5

ATM | Offering amount: $39,966,424

May 14, 2024

424B5

ATM | Offering amount: $40,000,000

Mar 22, 2024

424B5

SHELF OFFERING | Shares amount: 13,461,540 | Share price: $1.04

Feb 6, 2024

Registrations

TYPE

HEADLINE

FILED AT

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 29, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 29, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Jun 11, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 29, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 29, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Dec 9, 2024

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G

BlackRock, Inc. (Filed by)

Jul 29, 2026

Bradsher Neal C (Reporting)

Jul 2, 2026

Jayasuriya Anula (Reporting)

Jul 2, 2026

Mulroy Michael H. (Reporting)

Jul 2, 2026

ANDREWS DEBORAH J (Reporting)

Jul 2, 2026

Russell Angus C. (Reporting)

Jul 2, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Mar 24, 2026

CORRESP

Form CORRESP - Correspondence

Mar 19, 2026

LETTER

Form UPLOAD - SEC-generated letter

Mar 16, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

May 15, 2024

EFFECT

Form EFFECT - Notice of Effectiveness

Mar 22, 2021

EFFECT

Form EFFECT - Notice of Effectiveness

Mar 22, 2021

Lineage Cell Therapeutics, Inc. LCTX · SEC Filings